Relative increase in TV prevalence from t=0 (%); median [IQR] | ||||
Scenario 1 | ||||
Years after changes to cervical screening programme | 5 | 10 | 15 | 20 |
HR HPV prevalence fixed | 1.9 [1.6, 2.3] | 3.2 [2.3, 4.3] | 4.9 [3.3, 7.8] | 6.8 [4.4, 11.5] |
HR HPV prevalence continues to decrease at current rate | 1.9 [1.6, 2.3] | 3.4 [2.5, 4.6] | 5.5 [3.7, 9.0] | 7.8 [5.2, 13.5] |
Scenario 2 | ||||
Years after changes to cervical screening programme | 5 | 10 | 15 | 20 |
1.4 [1.2, 1.5] | 1.9 [1.6, 2.3] | 2.5 [2.0, 3.3] | 3.0 [2.4, 4.5] | |
Scenario 3 | ||||
Years after changes to cervical screening programme | 5 | 10 | 15 | 20 |
HR HPV prevalence fixed | 1.9 [1.6, 2.4] | 3.4 [2.5, 4.6] | 5.6 [3.6, 8.8] | 8.1 [4.9, 12.8] |
HR HPV prevalence continues to decrease at current rate | 1.9 [1.6, 2.4] | 3.5 [2.5, 4.8] | 6.0 [3.8, 9.5] | 8.8 [5.4, 14.5] |
*Median baseline prevalence for the 50 selected simulations was 0.40% (IQR [0.10%, 0.78%]). Absolute increase in TV prevalence is calculated as the difference between the individual prevalence at t=x (where x=5, 10, 15 or 20 years) and the individual prevalence at baseline for each of the 50 selected simulations, and for each of the three scenarios; the median and IQR are then calculated accordingly. Similarly, relative increase in TV prevalence is calculated as the individual prevalence at t=x divided by the individual baseline prevalence for each of the 50 simulations at a given time point. For this reason, the relative increase in TV prevalence does not exactly correspond to the median prevalence at t=x (0.40%+median absolute increase in TV prevalence at t=x) divided by the median baseline prevalence (0.40% at t=0).
HPV, human papillomavirus; HR, high risk; TV, Trichomonas vaginalis.